CLOs on the Move

Terumo Blood and Cell Technologies

www.terumobct.com

 
Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries. As the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction, we believe in the potential of blood to do even more for patients than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers. Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to our vision of ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.terumobct.com
  • 10811 W Collins Avenue
    Lakewood, CO USA 80215
  • Phone: 303.232.6800

Executives

Name Title Contact Details
Elizabeth Reagan
Assistant General Counsel, Director of Intellectual Property Profile
Janet Johnson
Vice President, Global Regulatory Affairs Profile

Similar Companies

Viela Bio

Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.

Inceptor Bio

Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.

Mirna Therapeutics

Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.

Principia Biopharma

Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.

Lathrop

Lathrop is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.